All Outputs (93)

Lack of diastolic reserve in patients with heart failure and normal ejection fraction (2009)
Journal Article
Chattopadhyay, S., Alamgir, M. F., Nikitin, N. P., Rigby, A. S., Clark, A. L., & Cleland, J. G. F. (2010). Lack of diastolic reserve in patients with heart failure and normal ejection fraction. Circulation. Heart failure, 3(1), 35-43. https://doi.org/10.1161/CIRCHEARTFAILURE.108.824888

Background-The genesis of symptoms in patients with heart failure (HF) and normal ejection fraction (HFNEF) is unclear. Most investigations of HFNEF have focused on cardiac function at rest although most of these patients are breathless only on exerc... Read More about Lack of diastolic reserve in patients with heart failure and normal ejection fraction.

Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT (2009)
Journal Article
Siegelaar, S. E., Kilpatrick, E. S., Rigby, A. S., Atkin, S. L., Hoekstra, J. B. L., & DeVries, J. H. (2009). Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia, 52(10), 2229-2232. https://doi.org/10.1007/s00125-009-1473-x

Acquired microcephaly: causes, patterns, motor and IQ effects, and associated growth changes (2009)
Journal Article
Baxter, P. S., Rigby, A. S., Rotsaert, M. H. E. P. D., & Wright, I. (2009). Acquired microcephaly: causes, patterns, motor and IQ effects, and associated growth changes. Pediatrics, 124(2), 590-595. https://doi.org/10.1542/peds.2008-2784

OBJECTIVES: The goals were to identify and to classify causes and growth patterns of acquired (or progressive) microcephaly and to look for hypothesized correlations between causes, growth patterns, and developmental quotient/IQ. METHODS: Fifty-one c... Read More about Acquired microcephaly: causes, patterns, motor and IQ effects, and associated growth changes.

Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes (2009)
Journal Article
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2009). Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care, 32(10), 1901-1903. https://doi.org/10.2337/dc09-0109

OBJECTIVE This study analyzed data from the Epidemiology of Diabetes Interventions and Complications (EDIC) study to see whether longer-term follow-up of Diabetes Control and Complications Trial (DCCT) patients reveals a role for glycemic instability... Read More about Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes.

Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey (2008)
Journal Article
Velavan, P., Khan, N. K., Goode, K., Rigby, A. S., Loh, P. H., Komajda, M., Follath, F., Swedberg, K., Madeira, H., & Cleland, J. G. (2010). Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey. International journal of cardiology, 138(1), 63-69. https://doi.org/10.1016/j.ijcard.2008.08.004

Objective: To identify factors associated with short term mortality in hospitalised patients with heart failure. Background: Hospitalisation is frequent in patients with heart failure and is associated with a high mortality. Methods: The Euro Heart F... Read More about Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey.

Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease (2008)
Journal Article
Wakil, A., Rigby, A. S., Clark, A. L., Kallvikbacka-Bennett, A., & Atkin, S. L. (2008). Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. European journal of endocrinology, 159(4), R11-R14. https://doi.org/10.1530/eje-08-0365

OBJECTIVE: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyp... Read More about Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.

A1C variability and the risk of microvascular complications in type 1 diabetes: Data from the diabetes control and complications trial (2008)
Journal Article
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2008). A1C variability and the risk of microvascular complications in type 1 diabetes: Data from the diabetes control and complications trial. Diabetes Care, 31(11), 2198-2202. https://doi.org/10.2337/dc08-0864

OBJECTIVE—Debate remains as to whether short- or long-term glycemic instability confers a risk of microvascular complications in addition to that predicted by mean glycemia alone. In this study, we analyzed data from the Diabetes Control and Complica... Read More about A1C variability and the risk of microvascular complications in type 1 diabetes: Data from the diabetes control and complications trial.

The timing of development and subsequent clinical course of heart failure after a myocardial infarction (2008)
Journal Article
Torabi, A., Cleland, J. G., Khan, N. K., Loh, P. H., Clark, A. L., Alamgir, F., Caplin, J. L., Rigby, A. S., & Goode, K. (2008). The timing of development and subsequent clinical course of heart failure after a myocardial infarction. European Heart Journal, 29(7), 859-870. https://doi.org/10.1093/eurheartj/ehn096

Aims: Myocardial infarction (MI) is a common cause of heart failure (HF), which may develop early and persist or resolve, or develop late. The cumulative incidence, persistence, and resolution of HF after MI are poorly described. The aim of this stud... Read More about The timing of development and subsequent clinical course of heart failure after a myocardial infarction.

Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes (2007)
Journal Article
Kilpatrick, E. S., Rigby, A. S., & Atkin, S. L. (2008). Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia, 51(2), 365-371. https://doi.org/10.1007/s00125-007-0883-x

Aims/hypothesisIt is not known whether mean blood glucose (MBG) predicts the risk of macrovascular complications in diabetes any differently from HbA1c. In this study we therefore analysed data from the Diabetes Control and Complications Trial (DCCT)... Read More about Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes.

Changes in body composition in patients with left ventricular systolic dysfunction initiated on beta-blocker therapy (2007)
Journal Article
Ingle, L., Rigby, A. S., Carroll, S., Butterly, R., King, R. F., Cooke, C. B., Cleland, J. G., & Clark, A. L. (2007). Changes in body composition in patients with left ventricular systolic dysfunction initiated on beta-blocker therapy. Experimental and Clinical Cardiology, 12(1), 46-47

Background: Increasing body mass index, cholesterol and body fat are associated with a better prognosis in patients with left ventricular systolic dysfunction (LVSD). Beta-blocker usage is associated with changes in body composition and increased bod... Read More about Changes in body composition in patients with left ventricular systolic dysfunction initiated on beta-blocker therapy.

Prognostic value of the 6 min walk test and self-perceived symptom severity in older patients with chronic heart failure (2007)
Journal Article
Ingle, L., Rigby, A. S., Carroll, S., Butterly, R., King, R. F., Cooke, C. B., Cleland, J. G., & Clark, A. L. (2007). Prognostic value of the 6 min walk test and self-perceived symptom severity in older patients with chronic heart failure. European Heart Journal, 28(5), 560-568. https://doi.org/10.1093/eurheartj/ehl527

Background: The 6 min walk test (6-MWT) is a simple and popular test for evaluating functional status in patients with chronic heart failure (CHF). However, the prognostic value of the 6-MWT in a large, representative sample of CHF patients, and in p... Read More about Prognostic value of the 6 min walk test and self-perceived symptom severity in older patients with chronic heart failure.

Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease (2006)
Journal Article
Ingle, L., Rigby, A. S., Nabb, S., Jones, P. K., Clark, A. L., & Cleland, J. G. (2006). Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease. European journal of heart failure, 8(3), 321-325. https://doi.org/10.1016/j.ejheart.2005.08.006

Background: The clinical determinants of six-minute walk test (6-MWT) performance in patients with left ventricular systolic dysfunction (LVSD) have rarely been investigated, and it is not clear whether they differ from patients referred for the asse... Read More about Clinical determinants of poor six-minute walk test performance in patients with left ventricular systolic dysfunction and no major structural heart disease.

The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure (2005)
Journal Article
Ingle, L., Shelton, R. J., Rigby, A. S., Nabb, S., Clark, A. L., & Cleland, J. G. (2005). The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure. European Heart Journal, 26(17), 1742-1751. https://doi.org/10.1093/eurheartj/ehi259

Aims: The 6-min walk test (6-MWT) is used to estimate functional capacity. However, in elderly patients with chronic heart failure (CHF): (i) 1 year reproducibility of the 6-MWT; (ii) sensitivity of the 6-MWT to self-perceived changes in symptoms of... Read More about The reproducibility and sensitivity of the 6-min walk test in elderly patients with chronic heart failure.